Back to results
US 2019/0314319 A1Published application
Combination therapy
AssigneeImbria Pharmaceuticals, Inc.
InventorAndrew D. Levin
Life of this patent
Estimating the term…
Abstract
The present disclosure provides certain combination therapy technologies that are particularly useful for treating one or more diseases, disorders, or conditions that may be related to abnormal metabolism. In some embodiments, provided technologies provides combinations of TCA cycle acids and ketone bodies. In some embodiments, provided technologies provides combinations of TCA cycle acids and other carboxylic acids.
Claims20
A compound having the structure of formula I:
- or a salt thereof, wherein:
- each of R1, R2 and R3 is independently —H, —OH, R, or R—C(O)O—, or may be independently and optionally taken together with a hydrogen atom on the carbon atom to which it is attached to form an oxo group;
- each R is independently linear or branched C1-C100 aliphatic wherein one or more —CH2— units are independently and optionally replaced with —O—, —C(O)—, —CH(OH)—, or —C(O)O—, and any two or more R groups may be linked by one or more linear or branched, bivalent or polyvalent, C1-C100 hydrocarbon group wherein one or more —CH2— units are independently and optionally replaced with —O—, —C(O)—, —CH(OH)—, or —C(O)O—;
- at least one of R1, R2 and R3 is R—C(O)O—;
- and
- wherein when each ester group of the compound of formula I is hydrolyzed into its corresponding —OH and —COOH groups, each hydrolysis product is independently a compound selected from a TCA cycle acid or a salt thereof, a C2-C20 diol or polyol, and R′—C(O)OH or a salt thereof;
- R′ is C1-C20 aliphatic wherein one or more —CH2— units are independently and optionally replaced with —O—, —C(O)—, —CH(OH)—, or —C(O)O—;
- and
- at least one hydrolysis product is a TCA cycle acid or a salt thereof.
6 more elements
Dependencies are inferred from the claim text.